- TRADE NAME: Ukoniq (TG Therapeutics)
- INDICATIONS:
Relapsed or refractory marginal zone lymphoma (subsequent to an anti-CD20-based regimen)
Relapsed or refractory follicular lymphoma (following previous systemic therap
- CLASS: Kinase inhibitor, Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
- HALF-LIFE: 91 hours
- FDA APPROVAL DATE: 02/05/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: May cause fetal harm when administered to a pregnant woman. Advise use of contraceptives.
- See adverse reactions attributed to class:
Phosphoinositide 3-kinase (Phosphatidylinositol 3-kinase) (PI3K) inhibitor
Please login to view the rest of this drug profile.
Page last updated 08/23/2024
